Graves' disease is characterized by an organ-specific autoimmune response resulting in the excessive production of thyroid hormones, leading to hyperthyroidism. At the forefront of Graves' disease diagnostic advancement, our company leads the way and showcases a range of unique strengths. With cutting-edge technology and a skilled team, we deliver holistic diagnostic solutions that facilitate early detection and personalized therapy strategies for Graves' disease.
Overview of Graves' Disease
Graves' disease is defined by thyrotoxicosis, triggered by the existence of circulating thyroid-stimulating antibodies (TSAb), which play a crucial role in both its extrathyroidal manifestations.
- Common symptoms linked to Graves' disease include weight loss, tremors, heat intolerance, and palpitations due to the excessive synthesis of thyroid hormones.
- The yearly occurrence rate of Graves' disease stands at 16 cases per 100,000 women and 3 cases per 100,000 men, typically appearing between the ages of 30 and 60 years.
Fig.1 Key factors to consider when diagnosing Graves' disease. (Metwalley, K. A., et al., 2023)
Pathogenesis of Graves' Disease
In Graves' disease, an autoimmune response triggers the generation of anti-thyroid-stimulating hormone receptor autoantibodies (TRAb) by B-cell clones that invade the gland. These antibodies attach to the thyroid-stimulating hormone receptors (TSH-R) on the thyroid gland, resulting in the unrestrained release of thyroid hormones. TRAb antibodies can be categorized based on their effects on the TSH-R as follows: TSAb, thyroid-blocking antibodies (TBAb), and neutral antibodies.
Fig.2 Genome-wide association scan in 30,000 individuals with autoimmune thyroid disease. (Grixti, L., et al., 2024)
Diagnostics Development for Graves' Disease
Antibody Testing
The precision and sensitivity of detecting TSI or TRAb antibodies have significantly improved. These antibodies are pivotal in developing Graves' disease and are often detected through radioimmunoassay or enzyme-linked immunosorbent assay (ELISA).
Genetic Testing
Several genes, including CTLA-4, TSH-R, CD40, PTPN 22, HLA, and CD25, are involved in the pathogenesis of Graves' disease. Identifying specific genetic factors associated with the onset of Graves' disease may help in early detection.
IVD Kits for Graves' Disease
| Kits |
Applications |
Method of detection |
| TSH Detection kit |
Quantitative measurement of human TSH in serum, plasma, and cell culture supernatants |
ELISA |
| TRAb Detection kit |
Quantitative measurement of TRAb |
ELISA |
| TSI Detection kit |
Determination of TSI content in human serum, plasma, and related samples |
ELISA |
Our Services
By utilizing state-of-the-art research and technological advancements, we offer advanced services in the development of IVD products for accurate detection. Additionally, we extend our expertise to include point-of-care testing and companion diagnostic development services, enabling swift diagnosis and personalized therapeutic approaches for Graves' disease.
IVD Product Development Services
Our commitment to precision and efficiency is exemplified through our continual refinement of diagnostic techniques and solutions, ensuring that professionals have access to reliable tools for diagnosing and treating Graves' disease. If you are interested in our services, please do not hesitate to contact us for additional information and pricing details regarding the services we offer.
References
- Metwalley, Kotb Abbass et al. "Graves' Disease in Children: An Update." Clinical medicine insights. Endocrinology and diabetes 16 (2023): 11795514221150615.
- Grixti, Lydia et al. "The genetics of Graves' disease." Reviews in endocrine & metabolic disorders 25.1 (2024): 203-214.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
